Stockscreener 앱 받기
5.11
1.73%
-0.09
시간 외 거래:
5.11
전일 마감가:
$5.20
열려 있는:
$5.1
하루 거래량:
375.09K
Relative Volume:
0.53
시가총액:
$621.12M
수익:
$58.49M
순이익/손실:
$-105.04M
주가수익비율:
-3.9317
EPS:
-1.2997
순현금흐름:
$-13.78M
1주 성능:
+7.81%
1개월 성능:
+13.30%
6개월 성능:
-32.67%
1년 성능:
-47.96%
1일 변동 폭
$5.08
$5.20
1주일 범위
$4.625
$5.46
52주 변동 폭
$3.30
$13.77
Immatics N V Stock (IMTX) Company Profile
IMTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
5.11 | 576.15M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 개시 | Piper Sandler | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2020-11-20 | 개시 | BofA Securities | Buy |
| 2020-09-22 | 개시 | Goldman | Buy |
| 2020-07-27 | 개시 | SVB Leerink | Outperform |
| 2020-07-24 | 개시 | Jefferies | Buy |
모두보기
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S - simplywall.st
The Manufacturers Life Insurance Company Sells 71,487 Shares of Immatics (NASDAQ:IMTX) - Defense World
Immatics: Q1 Earnings Snapshot - CT Insider
Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire
Immatics NV earnings missed by €0.07, revenue topped estimates - Investing.com South Africa
Immatics NV reports results for the quarter ended March 31Earnings Summary - TradingView
IMTX Sees Revenue Decline, Highlights Advances in Melanoma Thera - GuruFocus
Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs - TipRanks
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Immatics (IMTX) Projected to Post Quarterly Earnings on Tuesday - Defense World
(IMTX) Proactive Strategies - news.stocktradersdaily.com
Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals
Guggenheim Capital LLC Takes $101,000 Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Are Immatics N.V (IMTX) shares a good deal now? - uspostnews.com
Immatics Announces Upcoming Oral and Poster Presentation on IMA2 - GuruFocus
Immatics N.V. to Present Updated Data on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Nasdaq
Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire
Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan
Short Interest in Immatics (NASDAQ:IMTX) Declines By 20.7% - Defense World
Immatics N.V (NASDAQ: IMTX): Moving Toward A Higher Share Price - Stocksregister
(IMTX) Long Term Investment Analysis - news.stocktradersdaily.com
Immatics N.V (NASDAQ: IMTX): Can’t Stop The Stock’s Slide? - stocksregister.com
Immatics FY2025 EPS Estimate Lowered by Cantor Fitzgerald - The AM Reporter
FY2025 EPS Estimates for Immatics Decreased by Analyst - Defense World
Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Financial Contrast: Novonesis A/S (OTC:NVZMY) and Immatics (NASDAQ:IMTX) - Defense World
Research Analysts Set Expectations for Immatics Q1 Earnings - The AM Reporter
Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World
Immatics Reports Strong 2024 Financial Results and Progress - TipRanks
Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView
Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks
Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan
Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World
IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
(IMTX) Trading Report - Stock Traders Daily
Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World
Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Immatics N V (IMTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):